Page 43 - Haematologica Vol. 110 - January 2025

REVIEW ARTICLE - Molecular pathogenesis and novel treatments for CMML L. Marando et al.
92. Holderfield M, Lee BJ, Jiang J, et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature. 2024;629(8013):919-926.
93. Villaume MT, Arrate MP, Ramsey HE, et al. The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib. Exp Hematol. 2021;97:57-65.
94. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-Aza-2’-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008;28(2):752-771.
95. Thépot S, Lainey E, Cluzeau T, et al. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle. 2011;10(14):2323-2330.
96. Yabushita T, Chinen T, Nishiyama A, Asada S, Shimura R, Isobe T. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment. Cell Rep. 2023;42(9):113098.
97. Itzykson R, Santini V, Thepot S, et al. Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO network. J Clin Oncol. 2023;41(10):1888-1897.
98. Kobayashi Y, Munakata W, Ogura M, et al. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Int J Hematol. 2018;107(1):83-91.
99. Gillberg L, Ørskov AD, Nasif A, et al. Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: normalization of plasma vitamin C induces epigenetic changes. Clin Epigenetics. 2019;11(1):143.
100. Xie Z, McCullough K, Lasho TL, et al. Phase II study assessing safety and preliminary efficacy of high dose intravenous ascorbic acid in patients with TET2 mutant clonal cytopenias. Blood. 2023;142(Supplement 1):4611.
101. Yee KW, Chen HW, Hedley DW, et al. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia. Invest New Drugs. 2016;34(5):614-624.
102. Navada SC, Garcia-Manero G, OdchimarReissig R, et al. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: results of a phase 1 study. Leuk Res. 2020;94:106369.
103. Short NJ, Jabbour E, Naqvi K, et al. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019;94(1):74-79.
104. Steensma DP, Wermke M, Klimek VM, et al. Phase I first-in- human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021;35(12):3542-3550.
105. Assi R, Kantarjian HM, Garcia-Manero G, et al. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018;93(2):277-285.
106. Hunter AM, Newman H, Dezern AE, et al. Integrated human and murine clinical study establishes clinical efficacy of ruxolitinib in chronic myelomonocytic leukemia. Clin Cancer Res. 2021;27(22):6095-6105.
107. Padron E, Tinsley-Vance SM, DeZern AE, et al. Efficacy and safety of ruxolitinib for treatment of symptomatic chronic myelomonocytic leukemia (CMML): results of a multicenter
phase II clinical trial. Blood. 2022;140(Supplement 1):1101-1103. 108. Borthakur G, Popplewell L, Boyiadzis M, et al. Activity of the oral
mitogen-activated protein kinase kinase Inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016;122(12):1871-1879.
109. Feldman EJ, Cortes J, DeAngelo DJ, et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia. 2008;22(9):1707-1711.
110. Ravoet C, Mineur P, Robin V, et al. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ann Hematol. 2008;87(11):881-885.
111. Buckstein R, Kerbel R, Cheung M, et al. Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis. Leuk Res. 2014;38(7):756-763.
112. Kenealy M, Patton N, Filshie R, et al. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). Leuk Lymphoma. 2017;58(2):298-307.
113. Burgstaller S, Stauder R, Kuehr T, et al. A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1. Leuk Lymphoma. 2018;59(5):1121-1126.
114. Sekeres MA, Othus M, List AF, et al. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017;35(24):2745-2753.
115. Adès L, Duployez N, Guerci-Bresler A, et al. A randomised phase II study of azacitidine (AZA) alone or with lenalidomide (LEN), valproic acid (VPA) or idarubicin (IDA) in higher-risk MDS or low blast AML: GFM’s “pick a winner” trial, with the impact of somatic mutations. Br J Haematol. 2022;198(3):535-544.
116. Attar EC, Amrein PC, Fraser JW, et al. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res. 2013;37(9):1016-1020.
117. Sekeres MA, Watts J, Radinoff A, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher- risk MDS/CMML or low-blast AML. Leukemia. 2021;35(7):2119-2124.
118. Short NJ, Muftuoglu M, Ong F, et al. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol. 2023;16(1):73.
119. Patnaik MM, Ali H, Wang ES, et al. Tagraxofusp (SL-401) in patients with chronic myelomonocytic leukemia (CMML): updated results of an ongoing phase 1/2 trial. Blood. 2021;138(Supplement 1):538.
120. Patnaik MM, Sallman DA, Mangaonkar AA, et al. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 2020;136(7):909-913.
121. Hiwase D, Ross DM, Lane SW, et al. Lenzilumab in addition to azacitidine improves complete response rates in chronic myelomonocytic leukemia. Blood. 2023;142(Supplement 1):1847.
122. Brunner AM, Esteve J, Porkka K, et al. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024;99(2):E32-E36.
123. Saliba AN, Litzow MR, Gangat N, et al. Outcomes of venetoclax-
Haematologica | 110 January 2025
35